Contact
searchSearch
HMP Global
Login

Interactive Features

Quiz
Quiz: Does Pembrolizumab Plus Ipilimumab Lead to Antitumor Activity in Melanoma?
08/26/2021
True or false: In a recent phase 2 trial, pembrolizumab plus low-dose ipilimumab demonstrated antitumor activity and tolerability for patients with melanoma after anti-PD-1 immunotherapy failure.
True or false: In a recent phase 2 trial, pembrolizumab plus low-dose ipilimumab demonstrated antitumor activity and tolerability for patients with melanoma after anti-PD-1 immunotherapy failure.
True or false: In a recent phase...
08/26/2021
Oncology
Quiz
Quiz: Does Pembrolizumab Plus Ipilimumab Lead to Antitumor Activity in Melanoma?
08/26/2021
True or false: In a recent phase 2 trial, pembrolizumab plus low-dose ipilimumab demonstrated antitumor activity and tolerability for patients with melanoma after anti-PD-1 immunotherapy failure.
True or false: In a recent phase 2 trial, pembrolizumab plus low-dose ipilimumab demonstrated antitumor activity and tolerability for patients with melanoma after anti-PD-1 immunotherapy failure.
True or false: In a recent phase...
08/26/2021
Oncology
Test Your Knowledge
Quiz: Nomograms Developed to Predict Recurrences in Patients with T1 Melanomas
03/26/2021
True or False: The nomograms in this study can identify T1 melanoma patients at higher risk of either local, regional or distant recurrence.
True or False: The nomograms in this study can identify T1 melanoma patients at higher risk of either local, regional or distant recurrence.
True or False: The nomograms in...
03/26/2021
Oncology
Test Your Knowledge
Quiz: Combining Low-Dose Ipilimumab With Pembrolizumab in Melanoma
06/22/2020
True or False: In a phase 2 study, combining low-dose ipilimumab with pembrolizumab led to significant antitumor activity in patients with melanoma that progressed with a PD1 antibody.
True or False: In a phase 2 study, combining low-dose ipilimumab with pembrolizumab led to significant antitumor activity in patients with melanoma that progressed with a PD1 antibody.
True or False: In a phase 2...
06/22/2020
Oncology
Test Your Knowledge
Quiz: What Factors Increase Risk for AEs in Patients With Melanoma?
05/25/2020
True or False: The risk for immune-related adverse events in patients with advanced melanoma varies based on immune checkpoint inhibitor type and dose.
True or False: The risk for immune-related adverse events in patients with advanced melanoma varies based on immune checkpoint inhibitor type and dose.
True or False: The risk for...
05/25/2020
Oncology
Test Your Knowledge
Quiz: Can Adverse Events Indicate Pembrolizumab Activity in Stage III Melanoma?
03/06/2020
True or False: Immune-related adverse events can be indicative of pembrolizumab activity in patients with high-risk, stage III melanoma.
True or False: Immune-related adverse events can be indicative of pembrolizumab activity in patients with high-risk, stage III melanoma.
True or False: Immune-related...
03/06/2020
Oncology
Test Your Knowledge
Quiz: Mohs Micrographic Surgery vs Traditional Excision for Melanoma
02/13/2020
True or False: Compared with excision, Mohs micrographic surgery moderately improves overall survival in patients with early-stage invasive melanoma.
True or False: Compared with excision, Mohs micrographic surgery moderately improves overall survival in patients with early-stage invasive melanoma.
True or False: Compared with...
02/13/2020
Oncology

Recent News

News
Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma
04/02/2025
Emily Estrada
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose,...
04/02/2025
Oncology
News
Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
04/02/2025
Emily Estrada
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with...
04/02/2025
Oncology
News
Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma
04/02/2025
Emily Estrada
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more...
04/02/2025
Oncology
News
Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases
04/01/2025
Stephanie Holland
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a...
04/01/2025
Oncology
News
Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer
04/01/2025
Allison Casey
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective...
04/01/2025
Oncology
News
Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer
04/01/2025
Allison Casey
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of...
04/01/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
Allison Casey
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
FDA Approval
FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
03/28/2025
Stephanie Holland
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the...
03/28/2025
Oncology
FDA Approval
FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs
03/26/2025
Stephanie Holland
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the...
03/26/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use